Patent ID: 8519001

Claim:
A method of treating or suppressing a mitochondrial disorder or mitochondrial dysfunction, wherein the disorder or dysfunction is selected from the group consisting of Autistic Disorder, Friedreich's Ataxia, Huntington's Disease, Leber's Hereditary Optic Neuropathy (LHON), and Parkinson's disease, the method comprising administering to a subject a therapeutically effective amount of one or more compounds of Formula I: where R is selected from the group consisting of: where the * indicates the point of attachment of R to the remainder of the molecule; R 1 , R 2 , and R 3 are independently selected from hydrogen and C 1 -C 6 -alkyl; R 4 is C 1 -C 6 -alkyl; R 5 and R 6 are independently selected from hydrogen, hydroxy, alkoxy, C 1 -C 40 -alkyl, C 1 -C 40 -alkenyl, C 1 -C 40 -alkynyl, and aryl; where the alkyl, alkenyl, alkynyl, or aryl groups may optionally be substituted with —OR 10 , —S(O) 0-2 R 10 , —CN, —F, —Cl, —Br, —I, —NR 10 R 10′ , oxo, C 3 -C 6 -cycloalkyl, aryl, aryl-C 1 -C 6 -alkyl, heteroaryl, heterocyclyl, —C(O)—R 11 , —C(O)—C 0 -C 6 -alkyl-aryl, —C(O)—O—R 11 , —C(O)—O—C 0 -C 6 -alkyl-aryl, —C(O)—N—R 11 R 11 , —C(O)—N—C 0 -C 6 -alkyl-aryl, —N—C(O)—R 11 , —N—C(O)—C 0 -C 6 -alkyl-aryl; where the aryl, heteroaryl and heterocyclyl ring substituents may be further substituted with C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, oxo, hydroxy, C 1 -C 6 -alkoxy, —C(O)—C 1 -C 6 -alkyl and —C(O)—O—C 1 -C 6 -alkyl; and where one of the carbons of the alkyl, alkenyl, or alkynyl groups may be substituted with a heteroatom selected from —O—, —N— or —S—; R 10 and R 10′ are independently selected from the group consisting of hydrogen, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, aryl, aryl-C 1 -C 6 -alkyl, heteroaryl, heterocyclyl, —C(O)—H, —C(O)—C 1 -C 6 -alkyl, —C(O)-aryl and —C(O)—C 1 -C 6 -alkyl-aryl; R 11 and R 11′ are selected from hydrogen and C 1 -C 6 -alkyl; and M and M′ are independently selected from hydrogen, —C(O)—R 12 , —C(O)—C 1 -C 6 -alkenyl, —C(O)—C 1 -C 6 -alkynyl, —C(O)-aryl; —C(O)-heteroaryl, —C(O)O—R 12 , —C(O)NR 12 R 12 , —SO 2 OR 12 , —SO 2 —C 1 -C 6 -alkyl, —SO 2 -haloC 1 -C 6 -alkyl; —SO 2 -aryl, —SO 2 —NR 12 R 12 , —P(O)(OR 12 )(OR 12 ), and C-linked mono or di-peptide, where R 12 is hydrogen or C 1 -C 6 -alkyl optionally substituted with —OH, —NH 2 , —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , —C(O)—OH, —C(O)—O—C 1 -C 4 -alkyl or halogen; or a salt, a stereoisomer, or a mixture of stereoisomers thereof.